Department of General Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
Ghana Med J. 2024 Sep;58(3):192-197. doi: 10.4314/gmj.v58i3.3.
Previous studies suggest that patients' thyroid status might directly impact the course of Coronavirus disease 2019 (COVID-19). The objective of the study was to determine the clinical profile of COVID-19 patients with hypothyroidism and compare it with that of COVID-19 patients without hypothyroidism.
Retrospective observational study.
The study was conducted in a tertiary healthcare centre in Tamil Nadu between May and June 2021.
The study included 117 patients admitted with hypothyroidism and COVID-19 as well as 117 age and Gender matched COVID-19 patients without hypothyroidism.
Data regarding the demography, comorbidities, presenting symptoms, method of diagnosis of COVID-19, computed tomography (CT) severity score, Interleukin 6 (IL-6), D-dimer, oxygen requirement, number of days in hospital and outcome were collected for both groups. Data analysis was conducted, and p<0.05 was considered statistically significant.
The study comprised 234 patients over two months, from May to June 2021. Distribution of presenting symptoms showed that the hypothyroidism group presented with a higher incidence of fever (66.67%), loose stool (18.80%) and myalgia (7.69%). Results show that RTPCR+, O Requirement, death, D-dimer, IL-6, number of days admitted as well as CT-severity did not show any statistically significant differences (p>0.05) between both groups. The outcomes also showed that both groups reported four mortalities.
The results of the study help conclude that the hypothyroidism status of a COVID-19 patient is not associated with higher severity of clinical symptoms, deranged laboratory values as well as mortality.
None declared.
先前的研究表明,患者的甲状腺功能状态可能直接影响 2019 年冠状病毒病(COVID-19)的病程。本研究的目的是确定甲状腺功能减退症 COVID-19 患者的临床特征,并将其与无甲状腺功能减退症 COVID-19 患者进行比较。
回顾性观察性研究。
本研究于 2021 年 5 月至 6 月在泰米尔纳德邦的一家三级保健中心进行。
该研究纳入了 117 例因甲状腺功能减退症和 COVID-19 住院的患者,以及 117 例年龄和性别匹配的无甲状腺功能减退症 COVID-19 患者。
收集两组患者的人口统计学、合并症、临床表现、COVID-19 诊断方法、计算机断层扫描(CT)严重程度评分、白细胞介素 6(IL-6)、D-二聚体、氧需求、住院天数和结局数据。进行数据分析,p<0.05 为统计学显著差异。
本研究在 2021 年 5 月至 6 月的两个月内纳入了 234 例患者。临床表现分布显示,甲状腺功能减退症组发热(66.67%)、腹泻(18.80%)和肌痛(7.69%)的发生率较高。结果表明,两组间 RTPCR+、氧需求、死亡、D-二聚体、IL-6、住院天数和 CT 严重程度均无统计学显著差异(p>0.05)。结果还显示,两组均报告了 4 例死亡。
该研究结果有助于得出结论,COVID-19 患者的甲状腺功能减退症状态与更严重的临床症状、实验室值异常以及死亡率无关。
无。